FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that it will release its financial results for the fourth quarter and year ended December 31, 2006 following the close of the U.S. financial markets on Wednesday, February 21, 2007. PDL will hold a conference call to discuss these financial results, its commercial and clinical activities and its forward-looking information and guidance at 4:30 p.m. Eastern time on February 21, 2007.
The live webcast of the conference call will be available through the PDL website: http://www.pdl.com/. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A replay will be available at http://www.pdl.com/ starting approximately one hour after completion of the webcast.
An audio replay will also be available by telephone from approximately 6:30 p.m. Eastern time on February 21, 2007 through 6:30 p.m. Eastern time on March 22, 2007. To access the replay, dial 800-642-1687 from inside the U.S. and 706-645-9291 from outside the U.S.; enter conference ID number 8712465.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL's research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit http://www.pdl.com/.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL BioPharma, Inc.
